Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Filed May 1, 2025 · 10-Q · 31 days after period end · 0001178670-25-000052
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $594.19M | $494.33M | $319.29M | $213.26M |
| Net Income | -$18.25M | -$65.94M | -$174.10M | -$240.34M |
| EPS Diluted | -$0.14 | -$0.52 | -$1.40 | -$2.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 1, 2025 · 31 d after period end
